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Following introduction of antimycobacterial treatment of Buruli ulcer disease (BUD), several
clinical studies evaluated treatment outcomes of BUD patients, in particular healing times,
secondary lesions and functional limitations. Whereas recurrences were rarely observed,
paradoxical reactions and functional limitations frequently occurred. Although systematic
BUD control in Togo was established as early as 2007, treatment outcome has not been
reviewed to date. Therefore, a pilot project on post-treatment follow-up of BUD patients in
Togo aimed to evaluate treatment outcomes and to provide recommendations for optimiza-
tion of treatment success.
Methodology/Principal Findings
Out of 199 laboratory confirmed BUD patients, 129 could be enrolled in the study. The
lesions of 109 patients (84.5%) were completely healed without any complications, 5
patients (3.9%) had secondary lesions and 15 patients (11.6%) had functional limitations.
Edema, category III ulcers >15cm, healing times >180 days and a limitation of movement at
time of discharge constituted the main risk factors significantly associated with BUD related
functional limitations (P<0.01). Review of all BUD related documentation revealed major
shortcomings, in particular concerning medical records on adjuvant surgical and physiother-
apeutic treatment.
Conclusions/Significance
This study presents the first systematic analysis of treatment outcome of BUD patients from
Togo. Median times to healing and the absence of recurrences were in line with findings
reported by other investigators. The percentage of functional limitations of 11.6% was lower
than in other studies, and edema, category III ulcers, healing time >180 days and limitation
of movement at discharge constituted the main risk factors for functional limitations in
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Togolese BUD patients. Standardized treatment plans, patient assessment and follow-up,
as well as improved management of medical records are recommended to allow for intensi-
fied monitoring of disease progression and healing process, to facilitate implementation of
therapeutic measures and to optimize treatment success.
Author Summary
Buruli ulcer disease (BUD) is a mycobacterial skin disease which leads to large ulcerations
and causes disabilities in approximately 25% of the patients. Treatment consists of antimy-
cobacterial drugs, complemented by surgery and physiotherapy if necessary. Available
data on treatment outcome of BUD patients suggest that recurrences are rare; paradoxical
reactions and functional limitations, however, frequently occur. BUD control in Togo was
introduced already in 2007, but treatment outcome has not yet been reviewed. Therefore,
a clinical follow-up study assessed a cohort of 129 BUD patients at least six months after
the end of treatment. The lesions of 84.5% of the patients were healed without complica-
tions, 3.9% had secondary lesions, and 11.6%, a lower proportion than in other studies,
had functional limitations. Hereby, edema, category III ulcers, healing times>180 days,
and limitation of movement at discharge constituted the main risk factors. Review of all
BUD related documentation revealed a number of shortcomings, in particular concerning
medical records. In view of these findings, standardization of procedures for creating of
therapy plans, patient assessment and follow-up, as well as improved management of med-
ical records are recommended to facilitate implementation of therapeutic measures to
optimize treatment outcome and to allow for further evaluation.
Introduction
Buruli ulcer disease (BUD), caused byMycobacterium ulcerans, is a chronic, necrotizing skin
disease which has been reported from more than 30 countries worldwide with a focus in West
Africa [1]. BUD predominantly affects impoverished inhabitants of remote rural areas, approx-
imately 50% of the cases are children<15 years [1–2]. Initially BUDmanifests as painless nod-
ule, plaque, papule, or edema followed by large, painless ulcerations with characteristically
undermined edges [1–3]. Also cases with osteomyelitis occur [1–2, 4–5]. Lesions are divided
into three categories (I: single lesions,<5 cm diameter; II: single lesions, 5–15 cm diameter; III:
single lesions,>15 cm diameter, multiple lesions, lesions at critical sites, osteomyelitis) [2]. As
a result of scarring and contractures emerging during the healing process, especially patients
who are not treated early suffer long-term functional disability [1, 6]. As the mode of transmis-
sion of BUD has not been elucidated to date, proven strategies of prevention do not exist [1].
Early diagnosis and treatment are therefore core elements of BUD control which requires
strong commitment of health workers at community level, laboratory confirmation of 70% of
suspected cases by standardized diagnostic methods (preferably IS2404 PCR), and standardized
antimycobacterial treatment (rifampicin [R] in combination with streptomycin [S], alterna-
tively clarithromycin [C] for eight weeks), if necessary complemented by surgery and/or phys-
iotherapy [2, 7–9]. The WHO classified BUD as one of the currently five neglected tropical
diseases (NTDs) in line for the “innovative and intensified disease management (IDM)”
approach, demanding a major scaling up of active case detection, treatment, monitoring and
surveillance [10].
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Since the introduction of antimycobacterial combination therapy a number of clinical stud-
ies investigated the treatment outcome of BUD patients, in particular healing times, secondary
lesions and functional limitations. Whereas several authors observed healing of lesions of more
than 90% of patients receiving various antimycobacterial treatment regimens (RS8, RS4/RC4,
RS2/RC6) within twelve months [11–13], information on the time to healing varies. Nienhuis
et al. reported median healing times of category I lesions of 18 weeks, and 30 weeks for category
II and III lesions respectively [12]. Sarfo et al. further specified median healing times for nod-
ules of 8 weeks, for ulcers of overall 12 weeks (category I: 12 weeks; category II: 11 weeks; cate-
gory III: 15.5 weeks), and edema ranging from 2–48 weeks [11], Phillips et al. described
median healing times of 14 weeks (RS8) and 16 weeks (RS2RC6) [13], and Vincent et al.
observed median healing times of 12.6 weeks [5]. Available data from various studies also sug-
gest that healing of up to two thirds of patients occurs within about 25 weeks after onset of
treatment [5, 12–14].
Whereas proven recurrences were non-existent [11–13] or below 2% [15], paradoxical reac-
tions in terms of deterioration of lesions on antibiotic treatment or the appearance of second-
ary lesions during or after treatment, were described for individual patients [16–18] and for
larger patient cohorts. Nienhuis et al. found an increase in lesion size in up to 80%, and second-
ary lesions in 6% of the patients participating in the BURULICO antimicrobial trial in Ghana
[12, 19], O’Brien et al. described paradoxical reactions in 21% of an Australian patient cohort
[20], and Phillips et al. reported 9% of paradoxical reactions in a Ghanaian patient cohort par-
ticipating in a recent antimicrobial trial (RS2/RC6) [13]. Increases in lesion size were com-
monly observed during the first three months after onset of treatment [19–20], but also
delayed paradoxical reactions in terms of new lesions occurring up to thirteen months after the
end of antibiotic treatment are known [17–18].
Functional limitations were frequently observed. Data from two cohorts of laboratory con-
firmed BUD patients from Ghana treated between 2003 and 2005 (surgery with or without
concomitant antibiotic treatment), and between 2004 and 2009 (antimycobacterial treatment
with or without surgical intervention), suggested functional limitations in 27% and 33.3% of
the patients [21–22]. A comparison of two patient cohorts from the Democratic Republic of
the Congo treated between 2002 and 2004 (surgical treatment only) and 2005–2007 (the major-
ity of patients underwent surgery, more than 50% also received antimycobacterial therapy)
showed that 23.4% and 19.5% of the patients healed with complications [4]. A recent study
from Benin analyzed a cohort of more than 1000 BUD patients treated between 2005 and 2011
with antimycobacterial combination therapy and surgery if required, and reported 22% perma-
nent functional limitations one year after treatment [5].
Since the early 2000s, several investigators conducted in-depth assessments of functional lim-
itations and identified important risk factors for their development, in particular location on
joints and extremities of limbs, lesions>15 cm, and lesions at head and neck [21–28]. Beyond
that, Vincent et al. recently established a specific profile of risk factors for BUD patients from
Benin (edema, osteomyelitis, lesions>15 cm in diameter, multifocal lesions, healing times
>107 days) and introduced the operational definition “severe Buruli ulcer” to earmark patients
at risk for functional limitations for specific disability prevention measures [5].
In Togo, systematic BUD control was initiated in 2007. Whereas case finding, laboratory
confirmation and antimycobacterial treatment have been fully implemented [29–30], accom-
panying POD (prevention of disability) measures as outlined by the WHO [6] are not yet suffi-
ciently embedded in routine procedures, and treatment outcome has not been monitored.
This study presents the first analysis of treatment outcome of BUD patients in Togo, criti-
cally reviews procedures with a possible impact on the occurrence of complications, and pro-
vides recommendations for optimization of treatment success.
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Materials and Methods
Ethical considerations
Ethical clearance was obtained through the national Togolese ethics committee (‘‘Comité de
Bioéthique pour la Recherche en Santé”) at the University of Lomé (14/2010/CBRS) and the
study was approved by the ‘‘Ministère de la Santé de la République Togolaise” Lomé, Togo
(Ref. No. 0009/2011/MS/DGS/DPLET). Written informed consent (IC) was obtained in
French, if necessary translated into local languages, from all study participants and/or their
legal representatives if aged below 18 years.
Management of BUD in Togo
In Togo, BUD control mainly operates through a network of district based CLTs (“Contrôleurs
Lèpre-TB-Buruli”) and community based ASCs (“Agent Santé Communitaire”). CLTs regularly
conduct sensitization activities in villages and schools, furthermore perform active case finding
supported by ASCs who report patients with suspected BUD lesions to their corresponding
CLT. Due to extended coverage of sensitization activities, self-referrals of patients to the nearest
health post (“Unité de Soins Périphérique [USP]”) are on the rise. CLTs as well as USP head
nurses (“[ICP] Infirmier Chef Poste”) refer clinically suspected BUD cases to the regional refer-
ence hospital (“Centre Hospitalier Régionale [CHR] Tsévié”). At CHR-Tsévié a specifically
trained medical assistant (“point focal” [PF]) is in charge of further proceedings, such as physi-
cal examination, documentation on theWHO recommended BU 01.N and BU 01.R forms in
case of suspected recurrences [31], sample collection and initiation of laboratory confirmation
at the national hygiene institute (“Institute Nationale d’Hygiène [INH]”) according to standard-
ized procedures [29–30]. Whereas most patients with category I (partially also category II)
lesions are referred for outpatient treatment to USPs, the majority of patients with severe cate-
gory II and category III lesions, and children<15 years in general are treated at CHR-Tsévié.
Antimycobacterial treatment follows WHO recommendations and is complemented by surgical
intervention if required [2]. Wound management at CHR-Tsévié is performed by nurses, at the
USPs by the ICP, in both cases according to instructions of the PF. Patients who, according to
the judgment of the PF, require physical therapy are referred to physiotherapists who provide
treatment at the reference hospital, the USPs and also the patients homes. Currently 7 state
examined physiotherapists are seconded to treatment of BUD patients.
Study population
Eligible for the study were 199 PCR confirmed BUD patients originating from regions “Mari-
time”, “Savanes”, “Plateaux” and “Centrale” who were treated within the period from Septem-
ber 2007 to November 2013 with more than 6 months elapsed since the end of treatment.
Inclusion and exclusion criteria are shown in Table 1.
Clinical, epidemiological and treatment data were retrospectively compiled from existing
databases of previous studies which contained information retrieved from standardized WHO
BU 01.N and project specific laboratory data entry forms, and cross-checked with original
paper forms [29–30].
Study forms
To collect standardized data on treatment outcome a study specific form (S1 Form) was
employed which consisted of several sections: A-D) clinical/epidemiological baseline and treat-
ment data (taken from existing databases, prefilled prior to follow-up visits); E-F) information
on location of suspected secondary lesions (recorded in the field) and clinical samples collected
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for laboratory diagnosis; G-H) assessment of limitations of movement (LOM) and impairment
in daily activities (based on the questionnaire developed by Simonet V [32]; documented in the
field); I) recommendations for further medical treatment (issued after data analysis). In addi-
tion, for patients with open wounds at follow-up the BU 01.R form and a clinical record form
(as used routinely in Togo; S2 Form [30]) were filled in the field. S1 Table summarizes all
parameters collected for analysis.
Additional source materials
For patients with secondary lesions and functional limitations case histories were retrospec-
tively retrieved from medical records, where available. The distance from the patients’ location
of residence to CHR was obtained from logbooks of DAHW-T cars. In addition, documenta-
tion on physiotherapy was retrospectively reviewed, as far as accessible (“Fiche de bilan des
patients atteints de l’ulcère de Buruli” and “Prévention des incapacités liées à l’UB—formulaire
de base”; see S3 and S4 Forms).
Follow-up visits
A total of 25 follow-up visits to 29 USPs (corresponding to the catchment area of 61 villages)
were conducted in January-April 2013 (110 patients) and May-June 2014 (19 patients). In
advance, patients were grouped according to location of residence and accessibility of the near-
est USP and summoned by the responsible ICP upon instructions of the PF at a specific date. A
field team (surgeon, physiotherapist, medical assistant and PF) enrolled study participants at
the USPs and performed clinical examination and questioning according to the above
described study form (S1 Form) if informed consent was provided. For patients unavailable to
attend an attempt was made to retrieve them in their villages at a later date.
Patients whose lesions were healed without complications were discharged. From patients
with open wounds at examination (in that context referred to as secondary lesions) lesions
were measured and categorized according to WHO guidelines, and clinical samples were col-
lected for microbiological analysis. Patients with anatomical impairment (including excessive
scars and open wounds) were subjected to goniometric measurements according to the sagittal,
frontal, and transverse rotation method (SFTR) [33] and scars were measured by the surgeon
and medical assistant of the field team. Furthermore, these patients were questioned about the
functional impairment in daily life according to the questionnaire in part H of the study form
(S1 Form). Functional limitations were defined as BUD related anatomical impairment as
determined by goniometry and/or measurement of scars and were classified in type I (i.e. ana-
tomical impairment not hampering daily activities) and type II (i.e. anatomical impairment
hampering daily activities).
Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
IS2404 PCR confirmed BUD patient of any age Laboratory unconfirmed cases
Antimycobacterial treatment (RS8) was administered
(with or without completion of 56 doses) with or
without surgical interventions
Antimycobacterial treatment initiated before
September 2007 or after November 2013
>6 months elapsed since the end of antimycobacterial
treatment
<6 month elapsed since the end of
antimycobacterial treatment
written informed consent provided written informed consent not provided
Table 1 shows inclusion and exclusion criteria for study participants.
doi:10.1371/journal.pntd.0004170.t001
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Microbiological analyses
Collection of swab samples, fine-needle aspirates or 3mm punch biopsies as well as microscopy
and IS2404 qPCR followed standardized procedures at the laboratories of the INH, Lomé
accompanied by external quality assurance conducted at the Department for Infectious Dis-
eases and Tropical Medicine, Munich, Germany, as recently described [30]. For regular bacteri-
ological analysis, conducted in the accredited (COFRAC, ‘‘Comité Français d’Accréditation”
according to NF EN ISO/CEI 17025 [version 2005]) bacteriology unit of the INH, swab sam-
ples were inoculated on Chapman (mannitol-salt [MSA]) agar, blood agar and nutrient broth
(BioRad, Munich, Germany). Colonies indicative for Staphylococcus aureus were isolated from
MSA agar, analyzed by Gram staining, catalase and coagulase test, and subjected to susceptibil-
ity testing using the Kirby-Bauer disc diffusion method (15 antimicrobials) on Müller-Hinton
agar (BioRad) [34].
Statistical analysis
The study design was a non-randomized clinical cohort study. Statistical analysis (chi-square
test, including Fisher exact test) was carried out by EPIINFO 3.3.2. (CDC, Atlanta, GA, USA).
The results of statistical analyses were presented by P-values. Significant differences were
defined as P-values below 0.05.
Results
Patients enrolled and baseline data
Out of 199 BUD patients eligible for the study, 129 (64.8%) could be retrieved and enrolled as
follow-up patients in the study. Among the 129 follow-up BUD patients, 46.5% were male. At
the time of initial diagnosis 90 of 129 follow-up patients (69.8%) were below 15 years of age
(range 2–68 years, median 10 years, interquartile range [IQ] 7–16 years). The patients originated
from 6 districts of region “Maritime”. The distance from the place of residence to CHR-Tsévié
was known for 120 patients (93.0%) and was 1–23 km for 47 patients (39.2%) and 24–135 km
for 73 patients (60.8%). The duration of disease before clinical diagnosis was known for 128
patients (99.2%) and was 0–42 days for 81 patients (63.3%), and 43–3.600 days for 47 (36.7%)
patients. Baseline data and details on statistical analyses are provided in S2 Table.
Drop-out patients and baseline-data
Out of 199 BUD patients eligible for the study, 70 patients (35.2%) could not be enrolled
(drop-outs). Forty-three patients (61.4%) had moved to an unknown address, 24 (34.3%) were
not found and 3 were deceased (4.3%). Among the 70 drop-out patients, 52.9% were male (no
significant difference with the follow-up patients). At the time of initial diagnosis 36 of 70
drop-out patients (51.4%) were above 15 years of age (range 2–65 years, median 15.5 years, IQ
8.3–28 years) and significantly older than the follow-up patients (P<0.01%). The drop-out
patients originated from 6 districts of region “Maritime”, 2 districts of region “Plateaux”, 1 dis-
trict of region “Centrale” and 1 district of region “Savanes”. The distance from the place of resi-
dence to CHR-Tsévié was known for 60 drop-out patients (85.7%) and was 1–23 km for 34
patients (56.7%) and 24–135 km for 26 patients (43.3%); the drop-out patients lived signifi-
cantly closer to CHR Tsévié than the follow-up patients (P = 0.03%). The duration of disease
before clinical diagnosis was known for 69 drop-out patients (98.6%) and was 0–42 days for 21
patients (30.4%) and 43–3.600 days for 48 (69.6%) patients; the drop-out patients had a signifi-
cantly longer duration of disease than the follow-up patients (P<0.01). Baseline data and
details on statistical analyses are provided in S2 Table.
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Characteristics of initial lesions
At the time of initial diagnosis 73 of the 129 follow-up patients (56.6%) had ulcers and 56
patients (43.4%) had non-ulcerative lesions (nodule, n = 19 [33.9%]; plaque, n = 26 [46.4%];
edema, n = 11 [19.6%], 10 edemas evolved into an ulcer). Fifty-nine patients (45.7%) had cate-
gory I lesions, 44 patients had category II lesions (34.1%) and 26 patients (20.2%) had category
III lesions. Four of the patients with category III lesions had multiple lesions [multiple ulcers,
n = 2; ulcer and nodule, n = 1; ulcer and plaque, n = 1]). The localization of lesions was as fol-
lows: upper limbs, n = 51 (39.5%); lower limbs, n = 50 (39.8%); trunk/head, n = 28 (21.7%).
Lesions of 45 patients (34.9%) involved joints (category I, n = 23 [51.1%]; category II, n = 18
[40.0%]; category III, n = 4 [8.9%]). LOM at time of initial diagnosis were not documented.
Treatment and time to healing
Fourty-nine patients (38.0%; category I, n = 13; category II, n = 17; category III, n = 19)
received antimycobacterial treatment at CHR-Tsévié, 35 of these patients (71.4%) underwent
also surgery (excision and grafting, n = 11 [31.4%]; grafting, n = 23 [65.7%]; reconstructive sur-
gery, n = 1 [2.9%]). Out of these 35 patients, 10 had category I lesions, 8 had category II lesions,
and 17 had category III lesions. Eighty patients (62.0%) were referred to USPs (category I,
n = 46; category II, n = 27; category III, n = 7) for antimycobacterial therapy.
Among the 129 follow-up BUD patients, 126 patients completed antibiotic therapy (97.7%),
three patients (2.3%) did not (two patients were incompliant and for the third the reason was
not known). LOM after the end of treatment were documented for 126 patients (97.7%). Out
of them, 17 patients (13.5%; category I, n = 2; category II, n = 6; category III, n = 9) were dis-
charged with LOM.
The time to healing was known for 124 patients (96.1%) and ranged from 1–146 days for 63
patients (50.8%; significant correlation with category I lesions [P<0.01]), and 147–784 days for
61 patients (49.2%; significant correlation with category III lesions [P<0.01]). Stratified into
categories of lesions, 57 patients (46.0%) with category I lesions had a median healing time of
108 days (IQR: 93.5–149.5), 42 patients (33.9%) with category II lesions had a median healing
time of 151 days (IQR: 125.8–208), and 25 patients (20.1%) with category III lesions had a
median healing time of 256 days (IQR: 177–314). Among 41 patients with healing times of
more than 180 days, we also observed a correlation with functional limitations (P<0.01).
Physiotherapy
According to the BU 01.N forms, 117 out of the 129 follow-up BUD patients (90.7%) received
physiotherapy; however for 76 of these patients (65.0%) detailed documentation and phy-
siotherapeutic treatment protocols were not available. Nine follow-up BUD patients (7.0%) did
not receive physiotherapy for unknown reasons and for three patients (2.3%) this information
was not available. Eighteen patients (23.1%) were treated at CHR-Tsévié only, 60 patients
(76.9%) at USPs/patients homes and 39 patients (33.3%) at both locations. The number of ses-
sions was documented for 95 patients (81.2%): 24–99 sessions, n = 46 (48.4%); 100–520 ses-
sions, n = 49 (51.6%). Detailed physiotherapeutical treatment protocols, however, did not exist.
Findings at follow-up
Among the 129 follow-up BUD patients, the lesions of 109 patients (84.5%) were completely
healed without any complications. Five patients (3.9%) had secondary lesions (2 of them in
combination with functional limitations). WhereasM. ulcerans DNA was not detected in any
of the lesions, strains of S. aureus were isolated from two patients (one of them revealed a
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methicillin resistant S. aureus [MRSA]), in four cases the etiology of secondary lesions
remained unclear. Fifteen patients (11.6%) had functional limitations (type I, n = 5 [3.9%];
type II, n = 10 [7.8%]; two of them in combination with secondary lesions). From 80 patients
(62.0%) scars were measured. Out of them, 22 patients (27.5%) had scars with a diameter of
<5cm, 33 (41.3%) had scars with a diameter of 5–15cm, and 25 (31.3%) had scars with a diam-
eter of>15cm.
Risk factors for functional limitations
Among the clinical findings, functional limitations were significantly associated with healing
times>180 days (P<0.01), edema (P<0.01), and category III lesions (ulcers>15cm or multi-
ple lesions; P<0.01), and a documented LOM at time of discharge (P<0.01). Treatment related
factors significantly associated with functional limitations were surgery (P<0.01) and hospitali-
zation at CHR-Tsévié (P<0.01). S2 Table provides detailed risk factor analyses.
Discussion
This study provides the first analysis of treatment outcome of BUD patients in Togo. The
median times to healing as determined for various categories of patients lie within the range of
values reported by other authors. Likewise, our data also suggest that the lesions of approxi-
mately two third of the patients healed within about 25 weeks as reported by other authors [5,
11–14]. The absence of proven recurrences in our study is also in line with the low or non-
existing recurrence rate as observed by other investigators [11–13, 15]. As previously pub-
lished, one patient of our study cohort had developed a delayed paradoxical reaction 10 months
after the end of antimycobacterial treatment [18]. At the time of follow-up initial and second-
ary lesions were completely healed, the patient was therefore not included in the group of
patients with complications. Five patients had secondary lesions at the time of clinical exami-
nation which may be related to delayed type paradoxical reactions—this is however purely
speculative as the patients could not precisely indicate time of occurrence and clinical course of
the lesions. From the lesions of two of these patients S. aureus strains, one of themMRSA, were
isolated. Although this is the first reported case of MRSA from Togo, this finding was to be
expected as investigators from the neighboring countries Ghana and Benin have recently
shown that a high proportion of BUD lesions are colonized with S. aureus, and MRSA is fre-
quently isolated [35–37]. The Togolese MRSA patient was treated with vancomycin and
reportedly healed under antibiosis. It became however apparent that follow-up procedures for
identification of such complications are lacking, furthermore, a concept for antibiotic manage-
ment of super-infected BUD lesions does not exist.
A drawback of this study was that almost 35% of laboratory confirmed patients treated with
standardized antimycobacterial treatment could not be retrieved at follow-up visits. According
to medical records or BU 01.N forms, 60 of the drop-out patients (85.7%, out of them 58
patients without LOM [96.7%]) were completely healed at discharge. We could however not
assess long-term sequelae among the drop-out cohort. To avoid these lost to follow-ups, which
are likely to occur in mobile populations such as in Togo, we strongly recommend the intro-
duction of standardized follow-up procedures for BUD patients in Togo.
Among the cohort of BUD patients retrieved for follow-up the percentage of functional lim-
itations of 11.6% was lower than in other studies [4–5, 21–22]. However, we need to mention
that, in the absence of formal definitions, we introduced an operational definition of type I and
II functional limitations, therefore a direct comparison between our data and other studies
may not be possible without restrictions. Our data suggest that edema and category III ulcers, a
healing time>180 days as well as LOM at discharge constitute the main risk factors for
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functional limitations in Togolese BUD patients. The finding that hospitalization and surgical
treatment at CHR Tsévié were also associated with functional limitations can be explained by
the fact that 73% of patients with category III lesions were hospitalized at the reference center
and 89% of them underwent surgery.
In analogy with the operational definition of a “severe Buruli ulcer” as established by Vin-
cent et al. [5], we suggest to introduce criteria for the systematic identification of patients with
increased risk for functional limitations also into clinical management of BUD in Togo. We
propose to draw special attention to patients initially presenting with edema and category III
ulcers, furthermore—although our data did not show a significant correlation—joint involve-
ment as shown by other authors [21–23, 25–26].
A recent study emphasized the special importance of wound care for the prevention of BUD
related functional limitations [38]. Although according to our data most Togolese patients
with “severe Buruli ulcer” have already been hospitalized in CHR-Tsévié and received
advanced wound management, we recommend making it a general rule. Optimal wound man-
agement should consist of daily cleansing with saline solution (in cases of severe exudation
twice a day), removal of necrotic tissue, and use of vaseline dressing for prevention of drying of
the wound. In addition, consistent implementation of the POD related essential health inter-
ventions as outlined by the WHO are required and necessitate intensified training programs
for hospital staff, CLTs, ICPs and physiotherapists [6].
This study provided an excellent opportunity to review all BUD related documentation.
Clinical, epidemiological and treatment records on BU 01.N forms were for the most part com-
plete. The status of LOM at admission was however not documented, and information on evo-
lution of wounds during treatment was not available. For that reason we were not able to
retrospectively analyze the prevalence of early paradoxical reactions in terms of enlargement of
wounds. Likewise, extensions of lesions were only known for the time of admission and it was
impossible to keep track of lesions expanding over joints subsequent to initial diagnosis, which
may explain the absence of a significant correlation between lesions over joints and functional
limitations in our study cohort. Concerning surgery, operation reports were not available, and
information on indication, type and frequency of surgical interventions was largely retrieved
from handwritten notes and oral reports of PF and surgeons.
For more than 60% of the patients who allegedly had received physical therapy, written doc-
umentation was absent, and treatment protocols indicating the type of exercises performed did
not exist. Therefore, conclusions on the impact of physical therapy on prevention and clinical
improvement of functional limitations could not be drawn in this study.
In view of these findings, optimization of procedures accompanying or following antimyco-
bacterial treatment are highly recommended. Improvement of documentation of surgical and
physiotherapeutic interventions is required and shall be facilitated through filing maps.
Furthermore, to standardize concomitant physiotherapeutic measures, at the time of admis-
sion each patient should be seen by a physical therapist to decide on the general requirement of
physical therapy and to prepare a treatment schedule, if applicable. Upon completion of anti-
mycobacterial treatment, the PF at CHR-Tsévié and specially trained CLTs at the USPs respec-
tively, should conduct a standardized assessment for each patient to decide on discharge and/
or further therapeutic measures. The individual package of measures for each patient shall be
defined in a treatment schedule which is regularly monitored by PF and CLTs. As a general
rule, all patients should be followed until complete healing of the wound, afterwards at least
once per year for a five year period, thus facilitating timely recognition of two further risk fac-
tors for functional limitations, i.e. prolonged healing times and LOM at/after discharge, as well
as delayed paradoxical reactions. Regular feedback on fulfillment of treatment measures and
results of follow-up visits to the PNLUB-LP (“Programme National de Lutte contre l’Ulcère de
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Buruli, la Lèpre et le Pian”) is considered mandatory to enhance the transparency of the system
and to allow for further evaluation and improvement.
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